Eli Lilly CEO: We see a path to have an Alzheimer's disease-modifying drug

Eli Lilly CEO Dave Ricks how the drugmaker has worked for decades to find a way to treat Alzheimer's disease. The company says a Phase 2 trial of donanemab reveals that the drug can slow progression of the disease by 30%.